Ipca Laboratories (NSE:IPCALAB) Ending Cash Position: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:IPCALAB Ipca Laboratories Ltd NSE:IPCALAB
86 GF Score
Price ₹1,747.80
GF Value ₹1,604.39
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Ipca Laboratories Ending Cash Position?

Ipca Laboratories NSE:IPCALAB -0.63% 86 Ending Cash Position is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:IPCALAB with a GF Score™ of 86/100 and a GF Value™ of ₹1,604.39 (Fairly Valued). The stock has 6 warning signs investors should review.

Ipca Laboratories's Ending Cash Position for the quarter that ended in Mar. 2026 was ₹0 Mil.

Ipca Laboratories's annual Ending Cash Position increased from Mar. 2024 (₹7,558 Mil) to Mar. 2025 (₹9,246 Mil) and increased from Mar. 2025 (₹9,246 Mil) to Mar. 2026 (₹10,663 Mil).

Ipca Laboratories Ending Cash Position Related Terms

Ipca Laboratories Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Ipca Laboratories's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipca Laboratories Ending Cash Position Chart

Ipca Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9,909.30 15,789.80 7,557.90 9,246.30 10,663.00

Ipca Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:IPCALAB
86GF Score
Ipca Laboratories Ltd NSE:IPCALAB
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ipca Laboratories Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Ipca Laboratories's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=9246.2+1416.8
=10,663

Ipca Laboratories's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of ₹0 Mil mean?
Ipca Laboratories (NSE:IPCALAB) has a Ending Cash Position of ₹0 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Ipca Laboratories and its competitors.
Is Ipca Laboratories' Ending Cash Position too high?
Ipca Laboratories' current Ending Cash Position is ₹0 Mil. Overall, Ipca Laboratories has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ipca Laboratories' Ending Cash Position compare to ZTS?
Ipca Laboratories' Ending Cash Position of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Ipca Laboratories and its competitors. Ipca Laboratories's current Ending Cash Position is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipca Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ipca Laboratories (NSE:IPCALAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,604.39, compared to a current price of ₹1,747.80 — trading 8.9% above its estimated fair value. The current Ending Cash Position is ₹0 Mil. Ipca Laboratories' overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Ipca Laboratories (NSE:IPCALAB), the current Ending Cash Position is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ipca Laboratories (NSE:IPCALAB) Overvalued in 2026?

Based on GuruFocus' analysis, Ipca Laboratories stock appears to be overvalued. The current stock price of ₹1,747.80 is trading 8.9% above its estimated GF Value™ of ₹1,604.39. GuruFocus considers Ipca Laboratories to be Fairly Valued.

Key valuation signals for NSE:IPCALAB:

  • Ending Cash Position: ₹0 Mil
  • GF Value™: ₹1,604.39 vs. price of ₹1,747.80 (8.9% above fair value)
  • GF Score™: 86/100 with 6 warning signs

No single metric tells the full story. See the NSE:IPCALAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ipca Laboratories Business Description

Other Exchanges 524494:India
Address No. 48, 123 AB, 125 & 126 Kandivli Industrial Estate, Kandivli (West), Mumbai, MH, IND, 400067
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
86GF Score

Get the complete analysis for NSE:IPCALAB

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,747.80
Price
₹1,604.39
GF Value